Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ABCC9	10060	MINOXIDIL	CHEMBL802		ChemblInteractions
ABCC9	10060	GLYBURIDE	CHEMBL472	modulator	DrugBank	12145099, 16845255, 15023854, 17294036, 14672537
ABCC9	10060	SARAKALIM	CHEMBL2104449		ChemblInteractions
ABCC9	10060	NAMINIDIL	CHEMBL2105160		ChemblInteractions
ABCC9	10060	ADENOSINE TRIPHOSPHATE	CHEMBL14249		DrugBank	16845255, 16829188, 16897043
ABCC9	10060	PINACIDIL HYDRATE	CHEMBL1200338		ChemblInteractions

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ABCC9	rs2307024	TT	efavirenz	metabolism/PK	no	ON EFV-containing therapy for >7 days, absence of interacting drugs, no co-infection, drug intake 12 hrs (+/- 3 hrs) before blood draw, reported medication adherence above 90%. Receive 600 mg EFV once daily. Alleles given as C and T, and reported in CAR (NR1I3 gene).	Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections.	26774523	1447680461
ABCC9	rs704212	T	montelukast	metabolism/PK	yes	This variant is associated with reduced area under the plasma concentration-time curve (AUC) of montelukast (13.7% reduction per copy of each minor allele, P=2.19 × 10-4).	Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.	28940478	1449576525